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Abstract 
Class I major histocompatibility complexes (MHC) present peptide ligands on the cell surface for 
recognition by appropriate cytotoxic T cells. The unstable nature of unliganded MHC necessitates the 
production of recombinant class I complexes through in vitro refolding reactions in the presence of an 
added excess of peptides. This strategy is not amenable to high-throughput production of vast 
collections of class I complexes. To address this issue, we recently designed photocaged MHC 
ligands that can be cleaved by a UV light trigger in the MHC bound state under conditions that do not 
affect the integrity of the MHC structure. 
The results obtained with photocaged MHC ligands demonstrate that conditional MHC ligands can 
form a generally applicable concept for the creation of defined peptide-MHC complexes. However, the 
use of UV exposure to mediate ligand exchange is unsuited for a number of applications, due to the 
lack of UV penetration through cell culture systems and due to the transfer of heat upon UV irradiation 
which can induce evaporation. To overcome these limitations, here, we provide proof-of-concept for 
the generation of defined peptide-MHC complexes by chemical trigger-induced ligand exchange. The 
crystal structure of the MHC complex with the novel chemosensitive ligand, showcases that the ligand 
occupied the expected site binding site, in a conformation where the hydroxyl groups should be 
reactive to periodate. We proceed to validate this technology by producing peptide-MHC complexes 
that can be used for T cell detection. The methodology that we describe here should allow loading of 
MHC complexes with defined peptides in cell culture devices, thereby permitting antigen-specific T cell 
expansion and purification for cell therapy. In addition, this technology will be useful to develop 
miniaturized assay systems for performing high-throughput screens for natural and unnatural MHC 
ligands.  
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Introduction 
The concept of caged MHC class I ligands. The heterotrimeric major histocompatibility class I 
complexes (MHC class I) comprise an invariant light chain called β2-microglobulin, a polymorphic 
heavy chain and a peptide ligand normally 8 to 11 amino acids in length. Surveillance of the surface 
composed by both the peptide ligand and part of the heavy chain by T cell receptors on cytotoxic T 
cells forms the basis for a subsequent antigen-specific cytotoxic T cell response. Association of 
peptides with MHC class I is largely based on complementarity of amino acid side-chains at defined 
anchor positions in the MHC structure1,2 and by ionic interactions of their charged peptide acid and 
base termini3,4.  
The assembly of MHC class I complexes critically depends on availability of peptides that are 
essential for the stability of the MHC class I complex5,6, as evidenced by the effects of depletion of this 
peptide supply. This unstable nature of unliganded MHC demands the production of recombinant 
MHC through in vitro refolding reactions in the presence of an added excess of peptides7. However, 
the elaborate nature of these methods hampers their utility for parallel production of collections of 
peptide-MHC (pMHC) complexes and, as a consequence, our current understanding of T cell 
recognition is limited to only a small fraction of the available pMHC repertoire. To address this issue 
we have set out to develop MHC ligands that can be made to dissociate from the MHC complex by 
application of a defined trigger, thereby allowing parallel loading with ligands of interest. As a first 
generation of such conditional MHC ligands we have designed photocaged MHC ligands that can be 
cleaved by a UV trigger in the MHC bound state under conditions that do not affect the integrity of the 
MHC structure (Fig. 1a and b) (Celie et al, manuscript submitted)8-10. MHC class I complexes occupied 
with such photocaged ligands can be produced and purified using standard strategies. Cleaved 
fragments produced upon photolysis are no longer docked through double anchor residues and lose 
most of the original affinity resulting in dissociation from the MHC, leaving an unstable, peptide-
receptive complex that gradually denatures (Fig. 1a). Importantly, photolysis in the presence of 
another peptide ligand results in net ligand exchange, leading to a class I complex charged with an 
epitope of choice. Following the first description of this general approach in 2006, ligands that 
disintegrate upon application of a photostimulus have been developed for 9 different MHC products, 
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i.e. human MHC class I HLA-A1, -A2, -A3, -A11 and -B7,8-10 murine MHC class I H2-Db, H2-Kb 8,11,12 
and H2-Ld 13, and human MHC class II HLA DR214. 
 
Caged MHC class ligands and their use. Conditional exchange strategies enable the generation of 
peptide-receptive MHC complexes under physiological conditions and these MHC molecules have 
been used to identify peptide epitopes from disease-specific antigens that bind to the MHC allele 
under investigation. Furthermore, peptide-MHC complexes produced by MHC exchange reactions can 
be used to prepare collections of MHC tetramers (or other multimeric MHC reagents) for the detection 
of antigen-specific T cells by flow cytometry. Using such exchange tetramers we have validated the 
feasibility of large scale screening approaches by the definition of cytotoxic T cell epitopes within the 
H5N1 influenza A/Vietnam/1194/04 genome8. In subsequent work, this technology has proven useful 
for the identification of human and murine T cell epitopes in Chlamydia,11 murine gamma herpes 
virus,12 Toxoplasma gondii13 and melanoma-associated antigens (ref 10 and Reker-Hadrup et al. 
manuscript submitted).  
 
Conditional ligands and photo- vs chemocleavage. Although current phototriggered exchange 
methodology has proven very suitable for the parallel generation of MHC reagents, it is not optimal for 
all applications that can be envisaged for this technique. First, to reduce the risk of false positives (or 
negatives) resulting from high-throughput screening campaigns, uniform cleavage conditions need to 
be ascertained, while uniform parallel UV irradiation might be difficult to achieve when screening large 
numbers of potential ligands in minute volumes. Second, the deposition of pMHC complexes on solid 
surfaces to probe T cell function has been proven possible15-17, and the resulting pMHC microarrays 
may in principle be generated by in situ exchange reactions. However, the heat generated by UV 
irradiation of surfaces commonly in use in microarray technologies and resulting evaporation prohibits 
the use of a UV method for this particular application. Third, the in situ coating of conditional MHC 
complexes with peptide antigens by ligand exchange would form an attractive strategy for the 
generation of pMHC-coated culture devices that can be used for T cell expansion and enrichment. 
However, UV-irradiation is less suited for such tissue culture applications as common culture plastics 
hamper efficient transmission of UV light required for photo-uncaging.   
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For these reasons, we investigated the option of using a chemical trigger to effect peptide 
exchange reactions. Advantages are several-fold: exchange rates can simply be controlled by dosing 
the amount of chemical trigger reagent, while the trigger is compatible with sterile conditions where 
necessary and compatible with plastics, requirements not easily unified in a combination of UV 
irradiation and standard tissue culture practice. Importantly, a chemical trigger is readily available, 
allows the option of quenching of the triggering reagent and obviates the need for any special 
equipment, thereby opening MHC ligand exchange technology to the wider scientific community. 
 
Results 
Conditional ligand screening. We took advantage in our design of the reactivity of the vicinal diol 
moiety, that is cleaved by the mild oxidant NaIO4 under formation of two aldehyde species (Fig 1c), as 
periodate has proven compatible with (non-glycosylated) protein functionalities. As a building block for 
automated peptide synthesis we synthesized the isopropylidene protected diol (2R,3R)-4-N-Fmoc-
amino-2,3-dihydroxybutanoic acid IV which is easily prepared on a large scale by the method of 
Kamiya et al.18 starting from commercially available (−)-2,3-O-isopropylidene-D-erythronolactone I 
(Scheme 1). 
For efficient chemocleavage of the conditional peptide to occur, accessibility of the diol 
containing amino acid residue to periodate anions is required and the vicinal hydroxyl groups must be 
oriented in such a fashion that formation of the cyclic periodate ester intermediate is allowed sterically. 
Crystal structures of HLA-A2.1 charged with viral epitopes show that 73 to 83% of the peptide is 
deeply buried into the MHC peptide binding groove.19 A proven strategy for producing conditional 
MHC ligands is the replacement of one of the T cell receptor exposed amino acids in a known or 
predicted MHC ligand by an amino acid residue that is sensitive to a main chain breaking stimulus. In 
order to find a diol containing peptide that binds well to the MHC binding groove and that is, in turn, 
efficiently cleaved under mild oxidative conditions that do not compromise the integrity of the MHC 
protein, we scanned the diol containing γ-amino acid through the sequence of a number of known 
HLA-A2.1 nonameric and decameric epitopes between anchor positions p2 and p9 (for nonamers) or 
p10 (for decamers). As it seemed possible that periodate could diffuse into the peptide-binding groove, 
this unbiased approach for screening was chosen, rather than limiting such screening to known 
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exposed sites. Since the diol containing amino acid building block is a γ-amino acid, we hypothesized 
that two α-amino acid residues could be replaced by a single diol containing γ-amino acid, providing 
the rationale for our subsequent design. Accordingly, for the decameric epitopes we also synthesized 
their nonameric diol containing analogs. Parent peptides were included in the screen as controls. 
Peptides were generated by automated solid phase peptide synthesis and their purity was verified by 
LC/MS and found to be at least 85% for all peptides tested.  
As conditional ligand cleavage by photolysis is orthogonal to chemically induced ligand 
cleavage, we evaluated the generated set of diol-containing peptides for MHC binding capacity by 
phototriggered peptide exchange methodology in 96 well format using biotinylated HLA-A2.1 charged 
with conditional peptide GILGFVFJ1V, where J1 is the photocleavable residue 3-amino 3-(2-
nitro)phenyl propionic acid (see Table 1). Binding of the diol containing peptides to UV-vacated MHC 
complexes and susceptibility of the newly formed complex to NaIO4 mediated cleavage were both 
assessed with a streptavidin-based ELISA assay9. In addition, MHC complexes loaded with diol 
containing peptides that showed efficient cleavage by NaIO4 were subsequently tested for their 
capacity to allow chemically triggered peptide exchange. High photo-exchange efficiency combined 
with high NaIO4 susceptibility were obtained with peptides 3, 17, 24 and 44, all of them having the diol 
containing amino acid residue located on the p4 position. From this set, we selected peptide 3, 
NVLBMVATV, where B is the diol containing amino acid residue, as conditional chemosensitive 
peptide of choice, because it gave the highest level of MHC recovery after chemically triggered 
peptide exchange (see Supporting Fig. 1).  
 
Crystal structure of chemosensitive p*MHC complexes. A crystal structure of peptide 3, lodged in 
the MHC peptide binding groove was obtained by UV mediated in crystallo exchange methodology 
(Celie et al, manuscript submitted) to obtain the complex with the NLVBMVATV peptide within the 
MHC crystals. The efficiency of peptide exchange was validated and confirmed efficient replacement 
of the photocleavable peptide for peptide NLVBMVATV. The diol containing peptide introduced by in 
crystallo exchange is located within the MHC peptide binding groove between the two α-helices from 
the α1 and α2 domains of the MHC heavy chain (Fig. 2a) and is in a clear conformation (Fig. 2b). The 
2mFo-DF electron density map clearly shows the presence of peptide NLVBMVATV within the 
structure (Fig. 2b). We compared the structure of the peptide with its non-cleavable parent, 
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NLVPMVATV by superimposing the HLA-A2.1(Se-Mβ2m)::NLVBMVATV structure onto the previously 
solved HLA-A2.1::NLVPMVATV structure (Celie et al., manuscript submitted) (Fig. 2c). The peptides 
show a nearly identical structure, except for p4 and p5, where the diol containing peptide clearly 
adopts a different conformation. The diol residue was found to significantly protrude from the MHC 
peptide binding groove, making it accessible to the oxidizing reagent (Fig. 2a). Surface exposure of 
the p4 residue of the peptide is also observed in the parent structure and in other reported crystal 
structures of HLA-A2.1 loaded with various viral epitopes19. The dihedral angle between the vicinal 
hydroxyl groups however, seems to be limited to 70 degrees, which is apparently sufficient for reaction 
with the periodate anion20. Information on periodate reactivity towards 1,2-diols is limited towards open 
chain (syn/anti) and conformationally locked diols (cis/trans), where trans diols are generally 
uncleavable. It is of note that the dihedral angle in our conformationally locked diol is considerably 
greater than that of common cis diols, although some conformational freedom within the crystal may 
well be allowed. However, the orientation of both hydroxyl groups in the structure suggests that there 
may be opportunities to enhance the cleavage rate by enforcing a cis-conformation of these reactive 
hydroxyl groups during chemical synthesis.  
 
Peptide cleavage and exchange kinetics. An LC/MS analysis of peptide 3 showed that upon 
treatment with NaIO4 the peptide is fully cleaved into the two anticipated fragments (Supporting Fig. 3). 
In a kinetic experiment using HLA-A2.1 charged with fluorescently labeled NLVBMC(Fl)ATV peptide 
(Fl = tetramethylrhodamine-5-maleimide), exchange with native NLVPMVATV triggered by the addition 
of 0.3 mM NaIO4 at rt was monitored by gel filtration HPLC (Fig. 3a). The higher retention time of MHC 
loaded with NLVBMC(Fl)ATV compared with MHC charged with NLVPMVATV is a consequence of 
the apolar character of the first. Fig. 3a shows that 2 h incubation is sufficient for >98% loss of the 
conditional ligand. In a control experiment, treatment of photolabile HLA-A2.1::KILGC(Fl)VFJ1L under 
the same conditions (0.3 mM NaIO4 and 50 μM NLVPMVATV) did not result in peptide exchange, not 
even after 16 h exposure to NaIO4 (Fig. 3c). The release of fluorescently labeled remnants from the 
MHC binding groove revealed first order reaction kinetics (Supporting Fig. 4) with a t1/2 of 0.51 h for 
the chemically triggered reaction, while for UV mediated cleavage a t1/2 of 0.11 h was observed. 
Notably, while chemo-exchange reactions led to a reduction of fluorescence signal of >98%, we 
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consistently found that photomediated exchange reactions do not progress beyond 92% reduction in 
fluorescence signal, which has also been noted and discussed elsewhere10.  
 
Generation of MHC multimers for T cell detection by chemo-exchange. We used refolded and 
biotinylated HLA-A2.1::NLVBMVATV for MHC exchange reactions and converted these MHC 
exchange reagents into tetramers by addition of phycoerythrin (PE) conjugated streptavidin. The 
resulting reagents were used to detect antigen-specific T cells in peripheral blood samples by flow 
cytometry. Chemo-exchange tetramers containing the influenza A M1(58-66) epitope GILGFVFTL stain a 
low-frequency M1(58-66)–specific T cells in peripheral blood from a healthy individual at least as 
efficiently as photo-exchange MHC class I tetramers (Fig. 4). 
Whereas photo-exchange tetramers containing the CMV pp65(495-503) epitope NLVPMVATV 
stain low-magnitude peripheral blood mononuclear cells (PBMCs) from an HLA-A2.1 positive 
individual, the corresponding chemo-exchange tetramers give lower staining efficiency. LC/MS 
analysis revealed that under the 0.3 mM NaIO4 conditions used for peptide exchange the methionine 
residue on position 5 is partially oxidized, thereby hampering recognition by the T cell receptor (TCR) 
(Supporting Fig. 5). However, replacement of the oxidizable methionine residue by its isosteric carba-
analog21, norleucine, resulted in successful labeling of CMV positive T cells, whereas application of 
oxa-isosteres for methionine and cysteine was less fruitful (see Supporting Fig. 6). Isosteric 
replacement also appeared useful for the detection of T cells specific for the EBV BMLF I(259-267) 
epitope, in which both a cysteine and methionine residue have been replaced by their carba-analogs 
(Fig. 5). It is noted that success of isosteric replacement is to some extent donor dependent, as we 
have observed cases in which isosteric replacement leads to reduced staining efficiency, presumably 
reflecting a high requirement for complementarity required by the involved T cell receptors (data not 
shown).  
The conditional ligand NLVBMVATV is based on the CMV pp65(495-503) peptide. Although the 
TCR exposed surface of NLVBMVATV deviates substantially from that of the parental peptide, there is 
a theoretical possibility that uncleaved peptide remaining after incomplete NaIO4 mediated cleavage 
would result in staining of CMV pp65(495-503)-specific T cells. However, analysis of PBMCs of a CMV 
positive donor with tetramers prepared from MHC monomers that have not been exposed to NaIO4 do 
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not display background staining (Supporting Fig. 5). Moreover, the HPLC data in Fig. 3 show that 
chemocleavage occurs with >98% efficiency. 
 
Chemo-exchange tetramers for T cell enrichment. MHC-based selection of antigen-specific T cells 
has been proposed as a strategy to boost melanoma-specific T cell responses in individuals with 
melanoma22 and to provide defined minor histocompatibility antigen-specific and virus-specific T cells 
to recipients of allogeneic stem cell transplants and other immunocompromised individuals23-28. To 
provide proof-of-principle for such MHC based T cell selection we used chemo-exchange tetramers in 
combination with magnetic cell sorting for the isolation of influenza A-specific T cells. As shown in Fig. 
6, a single round of MHC-based purification of influenza A M1(58-66)-specific T cells from peripheral 
blood of a healthy donor resulted in a 95 % pure influenza A-specific T cell population.  
 
Discussion 
Photomediated MHC exchange technology has shown its merit in various laboratories since we have 
introduced this technique three years ago8. An orthogonal technology that can be used under 
conditions in which UV-mediated ligand exchange is less feasible involves the use of a chemical 
trigger to effect peptide exchange reactions. The activating reagent must effect complete and rapid 
cleavage of the conditional peptide under conditions that do not compromise the functionality of the 
MHC protein. One example of chemical cleavage of peptide bonds under mild, bioorthogonal 
conditions is the cleavage of peptides and proteins at azido homoalanine promoted by reducing 
agents such as phosphines and thiols29. However, this cleavage reaction is incomplete under 
physiological conditions and we therefore focused our chemocleavage strategy on oxidative cleavage 
of the vicinal diol moiety by the mild oxidant NaIO4.  
In an unbiased approach we scanned a vicinal diol containing amino acid residue through 
various HLA-A2 epitopes with known or predicted affinity and we found that useful chemocleavable 
peptides have their diol containing residue located on TCR and solvent accessible positions p4 or p5. 
Accordingly, the replacement of an amino acid residue engaged in TCR interactions, e.g. indicated by 
known crystal structures, seems to be the strategy of choice to adapt the chemocleavage principle to 
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other MHC alleles. This would omit the necessity of scanning the chemosensitive amino acid residue 
through an epitope with known affinity. 
Our choice for an anti-oriented 1,2-diol amino acid building block was guided by the ease of 
synthesis of Fmoc protected building block IV from commercially available (−)-2,3-O-isopropylidene-D-
erythronolactone I in only three steps. However, the crystal structure of HLA-A2.1(Se-
Mβ2m)::NLVBMVATV obtained by in crystallo exchange indicated a dihedral angle between the 
conformationally restricted anti-hydroxyl groups that seems suboptimal for formation of the 
intermediate cyclic periodate ester20. Nevertheless periodate exposure resulted in >98% cleavage 
within 2 hours at rt. Periodate triggered MHC exchange may benefit from changing the vicinal diol 
residue to the syn enantiomer, which may favor formation of the cyclic periodate ester intermediate in 
the MHC bound state and thus increase the rate of the cleavage reaction. Furthermore, a faster 
cleavage reaction may allow the use of lower periodate concentrations for effective cleavage, which 
may reduce the occurrence of concomitant oxidation of sulfur containing amino acid residues. We are 
currently investigating this synthetically more demanding option. 
The observed reduced staining efficiency with epitopes containing methionine or cysteine 
residues due to partial oxidation of sulfur atoms during NaIO4 mediated exchange reactions was 
circumvented by their isosteric replacement with carba-analogs norleucine and 2-aminobutyric acid, 
respectively. N-terminal serine or threonine residues in exchange peptides are, however, not 
compatible with NaIO4 triggered peptide exchange, as their vicinal amino alcohol moiety is prone to 
oxidative cleavage. However, for T cell staining these particular N-terminal amino acid residues can be 
replaced by other periodate resistant residues, since p1 is not an MHC class I anchor position and is 
not involved in decisive interactions with the TCR.  
An important application of MHC reagents, use for T cell depletion or enrichment, requires 
MHC production under sterile conditions. Conditions that can easily be unified by the addition of 
defined chemicals. Hence, we envisage the use of sterile surfaces, such as tissue culture flasks or 
tubing, coated with conditional MHC complexes that can be charged with selected epitopes. Peptide 
exchange may then be effected in a closed sterile environment by the addition of a defined amount of 
a chemical effector agent. The simplicity of production of different pMHC complexes by MHC 
exchange may prove valuable for the production of a set of clinical grade MHC reagents for 
therapeutic purposes. The clinical potential of MHC multimer-based T cell isolation has already been 
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demonstrated28 and based on the rapid developments in adoptive T cell therapies30, we anticipate that 
MHC multimer-based adoptive T cell therapies will become a prevalent technique. 
UV mediated MHC activation often leads to activation of small molecules containing UV 
sensitive moieties (e.g. carbonyl or nitro groups), thereby creating reactive free radical particles and 
consequently false positives in small molecule screens (B.R., unpublished observation). However, 
chemically triggered vacation of the MHC binding groove does not have this problem and may find 
application in high-throughput screening for small molecule MHC binders, while blocking the chemical 
trigger by addition of a quenching reagent remains an option.  
In conclusion, we have shown proof-of-principle for chemically triggered ligand exchange. A 
chemical trigger that is readily available obviates the need for any special equipment, opening this 
technique to the broader scientific community. Development of variant chemosensitive ligands that are 
cleaved under milder conditions will transform this into a platform that can be implemented widely. 
 
Methods 
Protein expression and purification. MHC class I refolding reactions were performed as described9 
and class I complexes were purified by gel-filtration HPLC in PBS (pH 7.4). Biotinylation and MHC 
tetramer formation were performed as described9. 
 
Fmoc-diol building block and peptide synthesis. The isopropylidene protected diol (2R,3R)-4-
amino-2,3-dihydroxybutanoic acid (III), was obtained from commercially available (−)-2,3-O-
isopropylidene-D-erythronolactone (I) by the method of Kamiya et al.18. Subsequent Fmoc protection 
with fluorenylmethyl chloroformate using standard dioxane-10% aqueous NaHCO3 conditions 
furnished Fmoc-diol building block IV in 72% yield. MS (ESI): [M+H]+ calculated: 398.16, found 398.12. 
1H-NMR (400 MHz, d6-DMSO) δ 13.00 (bs, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.71 (d, J = 7.5 Hz, 2H), 
7.46 and 6.97-6.92 (t and m, J = 7.4 Hz, 1H, rotamers), 7.42 (t, J = 7.5 Hz, 2H), 7.33 (t, J = 7.5 Hz, 
2H), 4.60 (d, J = 6.8 Hz, 1H), 4.40-4.35 (m, 1H), 4.30 (d, J = 6.8 Hz, 2H), 4.22 (t, J = 6.8 Hz, 1H), 3.31-
3.28 and 2.90-2.97 (m, rotamers, 2H), 1.47 (s, 3H), 1.30 (s, 3H). Naturally occurring peptides and 
photosensitive and chemosensitive variants were synthesized by standard Fmoc solid phase peptide 
synthesis and their purity was checked by LC/MS and found to be > 85%. 
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Conditional peptide exchange and screening for diol peptides. The set of diol containing peptides 
was subjected to UV mediated peptide exchange with biotinylated conditional HLA-A2.1::GILGFVFJ1L 
following a protocol that we have reported previously9. Briefly, in a 96 well polypropylene plate 50 μL 
of 0.5 μM biotinylated HLA-A2.1::GILGFVFJ1L (where J1 is UV-cleavable 3-amino-3-(2-nitro)phenyl 
propionic acid) and 50 μM exchange peptide in PBS was subjected to UV irradiation (366 nm) for 1 h 
at rt. Following peptide exchange, the plate was divided into two parts of which one part was subjected 
to treatment with 1 mM NaIO4 for 2 h at 37 °C to enable diol peptide cleavage. A streptavidin based 
sandwich ELISA was performed as described previously9 to score for successful peptide exchange 
and NaIO4 mediated peptide cleavage (and hence MHC degradation). Briefly, wells of 96 well Nunc 
immunoplate® were coated with streptavidin and following UV-mediated peptide exchange, 
biotinylated monomers were added to the wells. Bound MHC class I is recognized by horseradish 
peroxidase conjugated anti-β2m antibodies (DakoCytomation). 2,2'-azino-bis(3-ethylbenzthiazoline-6-
sulphonic acid) (ABTS) was added as a substrate for horseradish peroxidase to give a green colored 
oxidation product, which is monitored at 405 nm, indicative of successful MHC rescue with exchange 
peptides. Absence of coloring after NaIO4 treatment of MHC monomers indicated efficient peptide 
cleavage. To produce MHC reagents by chemically induced MHC exchange, we exposed HLA-
A2.1::NLVBMVATV (0.5 μM in PBS, pH 7.4) in the presence of 50 μM of the indicated peptide to 
NaIO4 at the indicated concentration in PBS for 2 h at rt. 
 
Peptide exchange in MHC crystals. Crystallization of HLA-A2.1(Se-Mβ2m)::Se-MILGJ2VFJ1V was 
performed as described previously (Celie et al., manuscript submitted). The exchange of peptide 
NLVBMVATV in HLA-A2.1(Se-Mβ2m)::Se-MILGJ2VFJ1V crystals was performed by transferring HLA-
A2.1(Se-Mβ2m)::Se-MILGJ2VFJ1V crystals to 4 µl crystallization solution containing 5 mM 
NLVBMVATV peptide in the sub-wells of a 96-well Greiner Crystal Quick Low-Profile crystallization 
plate. Crystals in solution were exposed 3 to 6 times to UV light (366 nm UV lamp, 2x15W blacklight 
blue tubes, LxWxH 505x140x117 mm, Uvitec, UK, 10 cm distance from sample) for 10 minutes at 4 
°C, with 2 minutes intervals. After UV irradiation, the plate was sealed with Hampton ClearSeal and 
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left for 4 hrs at 20 °C, allowing cleaved peptide fragments to dissociate and to be exchanged for the 
NLVBMVATV peptide. Crystals were vitrified and stored at -80 °C.  
 
Data collection, processing and structure refinement. Diffraction data for HLA-A2.1(Se-Mβ2m):: 
NLVBMVATV were collected at a temperature of 100 K using synchrotron radiation on beamline PXI 
X06SA, SLS, Villigen, Switzerland. Data were collected on a single crystal at a wavelength of 0.979 Ǻ. 
The wavelength was optimized for measuring the anomalous scattering of the selenium atoms. All 
diffraction data were integrated with MOSFLM31 and scaled in SCALA32. Crystals belong to the 
monoclinic space group P21, with a β angle close to 90o degrees and are pseudo-merohedrally 
twinned. Molecular replacement using an HLA-2.1 structure with the ligand removed was performed 
with AMORE through the CCP4i interface33. The positioned model was refined in REFMAC34. Manual 
inspection, rebuilding and the placement of the peptide was done with Coot35. Restrain libraries for 
non-standard amino-acids were created in the CCP4i sketcher and LIBCHECK. Final refinement was 
performed in PHENIX36. The exchange efficiency was validated by measuring the anomalous density 
of selenium atoms in the β2m protein and residual anomalous density at the positions previously 
occupied by the Se atoms in position p1 of the UV conditional ligand. The anomalous difference map 
clearly shows the presence of selenium atoms for Se-M residues 0 and 99 in Se-Mβ2m, but no 
residual density for Se-M of the photosensitive conditional peptide (Supporting Fig. 2). The structure 
was validated in Coot and WHATCHECK37 and is submitted to the Protein Databank (XXX.pdb). 
Within the final model, 92.7% of the amino acids are in preferred regions of the Ramachandran plot, 
5.7% in allowed regions and 1.6% are considered outliers. 
 
Exchange Kinetics. Chemically induced exchange kinetics were monitored by gel-filtration HPLC on 
a Biosep SEC S-3000 column (Phenomenex) in line with a fluorescence detector by performing MHC 
exchange of HLA-A2.1 refolded with fluorescently labeled NLVBMVAC(Fl)V in the presence of 50 μM 
cytomegalovirus pp65(495-503) epitope NLVPMVATV. Labeling of peptides with tetramethylrhodamine-5-
maleimide (Tebu-bio) was performed as described10. Exchange was started by the addition of 0.3 mM 
NaIO4 in PBS at rt. Data were analyzed by using GraphPad Prism software (GraphPad).  
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Cells and flow cytometry. For analysis of MHC tetramer binding and T cell responses in human 
samples, peripheral blood mononuclear cells of healthy volunteers were obtained by Ficolll gradient 
separation. Cells were stained with the indicated MHC tetramers for 4 min at 37 °C. Subsequently, 
cells were incubated with anti-CD8 antibody (BD Biosciences) for 10 to 15 min at 15 to 25 °C. Data 
acquisition and analysis was carried out on a FACSCalibur (Becton Dickinson) using FlowJo software. 
 
T cell enrichment. For T cell enrichment using magnetic cell sorting with MACS™ beads, 2x107 
PBMCs of a healthy donor were stained with 50 μL of a sample of 12.5 μg/mL phycoerythrin-
conjugated diol exchange tetramers of HLA-A2.1::influenza A M1(58-66) epitope. Staining was 
performed at rt. for 30 min in Iscove’s medium supplemented with 10 % human serum. Subsequently, 
cells were washed with medium and 40 μL MACS™ anti- PE beads was added. After a 15 min 
incubation at 4 °C, cells were washed and enriched on a MACS™ column following the manufacturer’s 
protocol. After elution of enriched cells from the column, cells were restained with PE conjugated diol 
exchange tetramers of HLA-A2.1:: influenza A M1(58-66) and FITC-conjugated anti-CD8 antibody and 
analyzed by flow cytometry.  
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Figure and Scheme Legends 
 
 
Figure 1. The principle of conditional MHC class I. (a) Conditional MHC class I is treated with a 
trigger, which cleaves the conditional peptide ligand to afford two fragments that no longer meet 
minimal affinity requirements and dissociate from the peptide binding groove. The resulting ligand-
receptive MHC class I has a short half-life at 37 ºC if not stabilized by the binding of a ‘rescue’ ligand. 
(b) Photocleavage of a 2-nitrophenyl containing conditional peptide ligand triggered by 365 nm UV 
light38. (c) Chemo-cleavage of a vicinal diol containing conditional peptide ligand triggered by the 
addition of NaIO4. 
 
Figure 2. Crystal structure of HLA-A2.1(Se-Mβ2m)::NLVBMVATV. (a) Overall structure of HLA-
A2.1(Se-Mβ2m)::NLVBMVATV. HLA-A2.1 is shown as a cartoon with the α1 domain in cyan, the α2 
domain in slate, the α3 domain in marine and Se-Mβ2m in green. Peptide NLVBMVATV is 
represented as sticks, with carbons in yellow, nitrogen in blue, oxygen in red and sulfur in orange. (b) 
Peptide is shown in the same orientation as in (a), together with the final 2mFO-DFc electron density 
map (blue) displayed at a contour level of 1.0 sigma and a radius of 1.8 Å around the peptide. (c) 
Structure of HLA-A2.1::NLVPMVATV, (Celie et al., submitted for publication) is superimposed on the 
HLA A2.1(Se-Mβ2m)::NLVBMVATV structure to illustrate the conformational similarities. Peptide 
NLVBMVATV  is represented as in (b) and peptide NLVPMVATV is shown with carbons in cyan.  
 
Figure 3. Peptide exchange efficiency and kinetics as monitored by gel-filtration HPLC analysis using 
UV absorbance (230 nm, left) and fluorescence (550ex/567em, right) detection. (a) Chemo-exchange 
of 0.5 µM HLA-A2.1::NLVBMVAC(Fl)V by treatment with 0.3 mM NaIO4 in the presence of 50 µM 
NLVPMVATV at rt. (b) Photo-exchange of 0.5 µM HLA-A2.1::KILGC(Fl)VFJ1V by exposure to UV light 
(365 nm) in the presence of 50 µM NLVPMVATV at rt. (c) Treatment of HLA-A2.1::KILGC(Fl)VFJ1V 
with NaIO4 in the presence of NLVPMVATV. 
 
Figure 4. Detection of antigen-specific T cells using chemo-exchange MHC multimers. Analysis of 
MHC tetramer staining of peripheral blood mononuclear cells of a healthy donor with the indicated 
MHC tetramers: HLA-A2.1::influenza M1(58-66) obtained via UV exchange (top left), HLA-A2.1::influenza 
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M1(58-66) obtained via chemo-exchange (bottom). No staining is seen for conditional HLA-A2.1 loaded 
with diol peptide NLVBMVATV (top right). Numbers indicate the percentage of MHC tetramer+ cells of 
CD8+ cells. 
 
Figure 5. Staining of peripheral blood mononuclear cells of healthy donors with HLA-A2.1 exchange 
tetramers obtained by either UV or NaIO4 mediated exchange as indicated. CMV: CMV pp65(495-503) 
epitope NLVPMVATV; CMV-Met5Nle: CMV pp65(495-503) epitope in which methionine is replaced with 
norleucine (Nle); EBV: EBV-BMLF I(259-267) epitope; EBV-Cys3Abu-Met8Nle: EBV-BMLF I(259-267) 
epitope, in which cysteine is replaced with L-2-aminobutyric acid and methionine is replaced with 
norleucine; Numbers indicate the percentage of MHC tetramer+ cells of CD8+ cells. 
 
Figure 6. T cell enrichment using chemo-exchange tetramers for magnetic cell sorting. For T cell 
enrichment using magnetic cell sorting, peripheral blood mononuclear cells of a healthy donor were 
stained with PE-conjugated tetramers of HLA-A2.1::influenza A M1(58-66) obtained via chemo-exchange 
methodology. Attachment of the stained T cells to anti-PE MACS™ beads followed by purification 
using a magnetic column resulted in a T cell sample enriched from 0.3 % before treatment (left panel) 
to 95% pure influenza A M1(58-66)-specific T cells (right panel).  
 
Scheme 1. Synthesis of vicinal diol containing amino acid building block IV for use in Fmoc based 
automated peptide synthesis. a) potassium phtalimide, DMF, reflux. b) hydrazine, EtOH, reflux. c) 
FmocCl, NaHCO3-H2O, dioxane. 
 
Tables 
 
Table 1. Chemocleavable amino acid scan through various HLA-A2.1 epitopes and assessment of 
MHC binding and chemocleavage by ELISA.a
 
No
. Sequence 
No NaIO4 
treatment 
(% of 
control ± 
SEM) 
NaIO4 
treatment 
(% of 
control ± 
SEM) 
 No. Sequence 
No NaIO4 
treatment 
(% of 
control ± 
SEM) 
NaIO4 
treatment 
(% of 
control ± 
SEM) 
1 NLVPMVATVb 100 ± 0.0 81 ± 3.1  25 YLLPBGPRL 84 ± 3.6 12 ± 0.2 
2 NLBPMVATV 6 ± 1.4 2 ± 1.3  26 YLLPRBPRL 58 ± 4.7 8 ± 0.3 
3 NLVBMVATV 91 ± 8.0 4 ± 0.9  27 YLLPRRBRL 19 ± 1.9 3 ± 0.7 
4 NLVPBVATV 76 ± 5.6 12 ± 1.6  28 FLPSDFFPSVf 63 ± 3.5 50 ± 1.3 
5 NLVPMBATV 49 ± 1.9 11± 1.3  29 FLBDFFPSV 59 ± 3.6 42 ± 3.4 
6 NLVPMVBTV 2 ± 0.9 2 ± 1.0  30 FLPBFFPSV 61 ± 3.6 6 ± 0.1 
7 NLVPMVABV 2 ± 0.9 1 ± 0.9  31 FLPSBFPSV 66 ± 3.3 26 ± 0.4 
8 KILGFVFTVc 32 ± 7.6 39 ± 6.1  32 FLPSDBPSV 81 ± 2.9 49 ± 0.5 
9 KIBGFVFTV 7 ± 1.3 8 ± 0.4  33 FLPSDFBSV 81 ± 1.7 58 ± 2.0 
10 KILBFVFTV 50 ± 3.0 5 ± 0.0  34 ILAETVVAKVg 48 ± 3.0 40 ± 2.3 
11 KILGBVFTV 43 ± 2.6 7 ± 0.3  35 ILBTVVAKV 6 ± 0.8 6 ± 0.2 
12 KILGFBFTV 55 ± 5.0 3 ± 0.1  36 ILAETVVBV 48 ± 3.9 7 ± 1.0 
13 KILGFVBTV 48 ± 4.4 30 ± 1.2  37 ILABVVAKV 55 ± 3.0 3 ± 0.4 
14 KILGFVFBV 31 ± 3.1 20 ± 0.0  38 ILBTVAKV 41 ± 3.6 27 ± 0.6 
15 ILAETVAKVd 74 ± 9.9 61 ± 3.7  39 ILABVAKV 38 ± 2.9 12 ± 0.3 
16 ILBETVAKV 10 ± 1.5 5 ± 0.3  40 ILAEBAKV 68 ± 7.0 46 ± 1.7 
17 ILABTVAKV 71 ± 14.0 2 ± 0.9  41 ILAETBKV 16 ± 2.3 7 ± 0.8 
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18 ILAEBVAKV 66 ± 11.9 5 ± 0.2  42 SLYNTVATLh 52 ± 6.1 39 ± 2.2 
19 ILAETBAKV 53 ± 6.2 12 ± 0.3  43 SLBNTVATL 1 ± 0.9 -1 ± 0.1 
20 ILAETVBKV 52 ± 2.6 28 ± 0.6  44 SLYBTVATL 62 ± 8.3 2 ± 0.0 
21 ILAETVABV 45 ± 3.9 6 ± 0.5  45 SLYNBVATL 53 ± 6.5 2 ± 0.3 
22 YLLPRRGPRLe 66 ± 5.2 51 ± 3.0  46 SLYNTBATL 46 ± 6.6 28 ± 2.1 
23 YLBRRGPRL 7 ± 0.2 1 ± 0.5  47 SLYNTVBTL 0 ± 0.0 0 ± 0.0 
24 YLLBRGPRL 80 ± 4.2 8 ± 0.8  48 SLYNTVABL 2 ± 0.3 0 ± 0.3 
a) Following UV mediated ligand exchange with 0.25 μM HLA-A2.1::GILGFVFJ1L, 50 μM diol peptide 
and 1 hr irradiation at 365 nm an ELISA9 was performed with 5 nM exchanged HLA-A2.1 untreated or 
after treatment with 1 mM NaIO4 for 2 h at 37 ºC. Absorbance at 405 nm was normalized to 
exchanged HLA-A2.1::peptide 1 without NaIO4 treatment. b) cytomegalovirus pp65(495-503) c) influenza 
A Matrix 1(58-66) in which G1 is replaced with K for solubility reasons and in which anchor residue L9 is 
replaced with V for increased HLA affinity; d) SIFPEITHI score 34, predicted optimal binder using the 
SYFPEITHI dataset39 e) hepatitis C virus core protein(35-44) f) hepatitis B virus nucleocapsid(18-27), g) 
SIFPEITHI score 34, predicted optimal binder using SYFPEITHI dataset, h) HIV-1 (BRU) gag p17(76-
84). 
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